Valneva (NASDAQ:VALN) Trading 7.6% Higher – Should You Buy?

Valneva SE (NASDAQ:VALN)’s share price rose 7.6% during trading on Thursday . The company traded as high as $7.24 and last traded at $7.18. Approximately 35,366 shares traded hands during trading, a decline of 34% from the average daily volume of 53,530 shares. The stock had previously closed at $6.67.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Valneva in a report on Friday, January 31st.

Valneva Price Performance

The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. The stock’s fifty day moving average price is $4.57 and its 200-day moving average price is $5.66.

Institutional Investors Weigh In On Valneva

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC increased its holdings in shares of Valneva SE (NASDAQ:VALN) by 33.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 118,000 shares of the company’s stock after purchasing an additional 29,748 shares during the quarter. AlphaCentric Advisors LLC owned 0.15% of Valneva worth $717,000 at the end of the most recent reporting period. Institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.